Results 101 to 110 of about 25,099 (263)
Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state
Abstract INTRODUCTION The brain is a complex dynamical system, influenced by arousal state. Cortical synchrony supports information processing and is disrupted in Alzheimer's disease (AD). Locus coeruleus (LC) integrity and pupillometry index arousal system structure and function.
Michael C. B. David +12 more
wiley +1 more source
Switching cholinesterase inhibitors in patients with Alzheimer's disease
Despite recognition that cholinesterase inhibitors can provide clinical benefits for patients with Alzheimer's disease (AD), the average durations of treatment and beneficial effects are not optimal in all cases. This may be due to disappointing efficacy
Emre, M
core
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a networkmeta-analysis (Protocol) [PDF]
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of each cholinesterase inhibitor in the treatment of adults with VCI. To compare cholinesterase inhibitors for efficacy
Shenkin, Susan D. +5 more
core +1 more source
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem +5 more
wiley +1 more source
Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16.106 Patients [PDF]
We investigated the effect of cholinesterase inhibitors on all-cause discontinuation, efficacy and safety, and the effects of study design-, intervention-, and patient-related covariates on the risk-benefit of cholinesterase inhibitors for Alzheimer’s ...
Barceló, Maria A. +20 more
core +1 more source
Thiosemicarbazones generally show higher MAO‐B inhibitory potential than their corresponding semicarbazones, and particularly T6 is the most potent, which contains R = H and X = S in its Tail Unit, with an IC50 value of 6.45 µM with SI of 3.6. ABSTRACT Twenty semicarbazone and thiosemicarbazone derivatives (T1–T20) were synthesized and evaluated for ...
Sandeep Bindra +11 more
wiley +1 more source
Medications used in dementia: a review of evidence
Background Dementia is an acquired global impairment of intellect, memory and personality, without impairment of consciousness. It is usually progressive in nature. The management of dementia is mainly two faceted; pharmacological and non-pharmacological.
C. Suraweera, R. Hanwella, V.A. de Silva
doaj +1 more source
In this investigation, Withania somnifera root ethanol extract displays anti‐inflammatory and antidiabetic properties. Though compounds including withasomniferolide B and sitoindoside IX have been previously identified as phytoconstituents in the plant, in silico analysis from this study revealed them as new lead compounds that could act as potential ...
Lufuno Mulelu +4 more
wiley +1 more source
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng +16 more
wiley +1 more source
Aims: To assess variations in dementia treatment, diagnosis, and pathway practices across the memory services in Tees, Esk and Wear Valleys (TEWV) NHS Foundation Trust and how these compare to Trust and national policy.
Olusegun Sodiya +4 more
doaj +1 more source

